Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina

NCT03059251 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03059251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
August 31, 2017
Completion date
March 30, 2019
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia